Javascript must be enabled to continue!
Green Synthesis of Gelatin‐Lipid Nanocarriers Incorporating Berberis aristata Extract for Cancer Therapy; Physical Characterization, Pharmacological and Molecular Modeling Analysis
View through CrossRef
Abstract
Cancer remains strongly associated with morbidity and lethality posing a massive challenge to public health from decades. Thus, new interventions, effective and meaningful therapeutic approaches towards the treatment of cancer are urgently required. In this regard, nanotechnology offers an efficacious pharmacological application towards anticancer therapy. Therefore, the current study was aimed to develop
Berberis aristata
aqueous extract loaded gelatin lipid‐nanocarriers to explore their
in vitro
and
in vivo
antitumor properties. The extract loaded gelatin lipid nanoparticles were formulated by using double emulsion solvent evaporation method and physical characterization was performed using various techniques. Hydrodynamic diameter, zeta potential and polydispersity index (PDI) of GLN‐BA were observed as 322±7 nm, −31.49±4.85 mV and 0.397±0.102 mV, respectively. The extract was efficiently entrapped within the GLN (EE=79±11 %) and follow the diffusion type release mechanism. Moreover, transmission electron microscopy (TEM) demonstrated the spherical shaped smooth morphology of nanospheres.
In vitro
anticancer activity of GLN‐BA was performed by SRB assay and shown to demonstrate effective cytotoxicity (IC
50
=4.73±2.95
μ
g/mL) against MCF‐7 which was further quantitatively and qualitatively verified by flow cytometry, genotoxicity and DAPI staining. Induction of apoptotic bodies provides the evidence for apoptosis mediated cytotoxicity. Further,
in vivo
analysis on female mice was carried out to corroborate anticancer activity and was comparable to cisplatin. At 10
th
day, the GLN‐BA (10 mg/kg) prominently reduced the tumor volume to 35±11 % in consistent with cisplatin (3 mg/kg) which exhibited 41±5 % reduction. Moreover, molecular modeling analysis substantiates the stable nanoformulation encapsulating the BA bioactive constituent. Taken together, current findings supported the therapeutic effectiveness of BA encapsulated gelatin lipid nanoparticles towards breast cancer suggesting the use of medicinal plant as a prototype to treat tumor.
Title: Green Synthesis of Gelatin‐Lipid Nanocarriers Incorporating
Berberis aristata
Extract for Cancer Therapy; Physical Characterization, Pharmacological and Molecular Modeling Analysis
Description:
Abstract
Cancer remains strongly associated with morbidity and lethality posing a massive challenge to public health from decades.
Thus, new interventions, effective and meaningful therapeutic approaches towards the treatment of cancer are urgently required.
In this regard, nanotechnology offers an efficacious pharmacological application towards anticancer therapy.
Therefore, the current study was aimed to develop
Berberis aristata
aqueous extract loaded gelatin lipid‐nanocarriers to explore their
in vitro
and
in vivo
antitumor properties.
The extract loaded gelatin lipid nanoparticles were formulated by using double emulsion solvent evaporation method and physical characterization was performed using various techniques.
Hydrodynamic diameter, zeta potential and polydispersity index (PDI) of GLN‐BA were observed as 322±7 nm, −31.
49±4.
85 mV and 0.
397±0.
102 mV, respectively.
The extract was efficiently entrapped within the GLN (EE=79±11 %) and follow the diffusion type release mechanism.
Moreover, transmission electron microscopy (TEM) demonstrated the spherical shaped smooth morphology of nanospheres.
In vitro
anticancer activity of GLN‐BA was performed by SRB assay and shown to demonstrate effective cytotoxicity (IC
50
=4.
73±2.
95
μ
g/mL) against MCF‐7 which was further quantitatively and qualitatively verified by flow cytometry, genotoxicity and DAPI staining.
Induction of apoptotic bodies provides the evidence for apoptosis mediated cytotoxicity.
Further,
in vivo
analysis on female mice was carried out to corroborate anticancer activity and was comparable to cisplatin.
At 10
th
day, the GLN‐BA (10 mg/kg) prominently reduced the tumor volume to 35±11 % in consistent with cisplatin (3 mg/kg) which exhibited 41±5 % reduction.
Moreover, molecular modeling analysis substantiates the stable nanoformulation encapsulating the BA bioactive constituent.
Taken together, current findings supported the therapeutic effectiveness of BA encapsulated gelatin lipid nanoparticles towards breast cancer suggesting the use of medicinal plant as a prototype to treat tumor.
Related Results
Daruharidra (Berberis Aristata Dc): A Solution to Ailments in Present and Future
Daruharidra (Berberis Aristata Dc): A Solution to Ailments in Present and Future
Berberis aristata, generally known as Daruharidra because of yellow coloured wood, belongs to the family Berberidaceae. Approximately 500 species of genus Berberis are found Worldw...
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Evaluating the Science to Inform the Physical Activity Guidelines for Americans Midcourse Report
Abstract
The Physical Activity Guidelines for Americans (Guidelines) advises older adults to be as active as possible. Yet, despite the well documented benefits of physical a...
Phytochemical Profiling Of Berberis Aristata Roots: Identification Of Bioactive Compounds And Their Pharmacological Potential
Phytochemical Profiling Of Berberis Aristata Roots: Identification Of Bioactive Compounds And Their Pharmacological Potential
In Nepal Berberis aristata locally known as Chutro. It is a important highly medicinal plant used for the treatment of disease in traditional Ayurvedic and Himalayan medicine. The ...
[RETRACTED] Green Dolphin CBD Gummies - Reduce anxiety with improved better sleepless - Tincture Trial v1
[RETRACTED] Green Dolphin CBD Gummies - Reduce anxiety with improved better sleepless - Tincture Trial v1
[RETRACTED]Green Dolphin CBD Gummies Reviews (Price 2022) Shark Tank | Scam or Legit?Overview –Green Dolphin CBD GummiesOrder Now From Officials Website : Click HereProduct Name - ...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract
Introduction
Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Abstract 4154: Cancer cells exhibit novel metabolic vulnerabilities when exposed to low lipid environments
Abstract 4154: Cancer cells exhibit novel metabolic vulnerabilities when exposed to low lipid environments
Abstract
Cancer cell metabolism is significantly influenced by microenvironmental factors such as nutrient availability, which can vary across different tissues and ...

